Skip Page Header

Home > An introduction to extended-release injectable naltrexone for the treatment of people with opioid dependence.

Substance Abuse and Mental Health Services Administration. (2012) An introduction to extended-release injectable naltrexone for the treatment of people with opioid dependence. Dublin, Ohio: Substance Abuse and Mental Health Services Administration.

[img] PDF (An introduction to extended-release injectable naltrexone) - Published Version
655kB
[img]
Preview
PDF (Drug and Alcohol Findings summary of SAMHSA Advisory) - Supplemental Material
50kB

The US Food and Drug Administration (FDA) approved extended-release injectable naltrexone (Vivitrol) in October 2010 to treat people with opioid dependence. This medication provides patients with opioid dependence the opportunity to take effective medication monthly, as opposed to the daily dosing required by other opioid dependence medications (i.e., methadone, buprenorphine, oral naltrexone). Extended-release injectable naltrexone was approved by FDA in 2006 to treat people with alcohol dependence.

This US Advisory provides behavioral health professionals—including substance abuse treatment specialists—and primary care medical providers (who treat people with opioid dependence) with an introduction to extended-release injectable naltrexone. It includes succinct information about extended-release injectable naltrexone, how it compares with other medication-assisted treatment (MAT) options, and clinical strategies that may be used to select, initiate, and administer treatment.


Item Type
Report
Publication Type
International, Guideline, Report
Drug Type
Opioid
Intervention Type
Drug therapy, Treatment method
Date
2012
Pages
8 p.
Publisher
Substance Abuse and Mental Health Services Administration
Corporate Creators
Substance Abuse and Mental Health Services Administration
Place of Publication
Dublin, Ohio
Volume
11
Number
1
EndNote
Accession Number
HRB (Electronic Only)

Repository Staff Only: item control page